Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection

Authors

Peter J Mazzone, Cleveland Clinic
David Gierada, Washington University School of Medicine in St. Louis
et al.

Journal

Cancer Discovery

Publication Date

11-1-2024

Volume

14

Issue

11

First Page

2224

Last Page

2242

Document Type

Open Access Publication

DOI

10.1158/2159-8290.CD-24-0519

Rights and Permissions

Mazzone PJ, Bach PB, Carey J, Schonewolf CA, Bognar K, Ahluwalia MS, Cruz-Correa M, Gierada D, Kotagiri S, Lloyd K, Maldonado F, Ortendahl JD, Sequist LV, Silvestri GA, Tanner N, Thompson JC, Vachani A, Wong KK, Zaidi AH, Catallini J, Gershman A, Lumbard K, Millberg LK, Nawrocki J, Portwood C, Rangnekar A, Sheridan CC, Trivedi N, Wu T, Zong Y, Cotton L, Ryan A, Cisar C, Leal A, Dracopoli N, Scharpf RB, Velculescu VE, Pike LRG. Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection. Cancer Discov. 2024 Nov 1;14(11):2224-2242. doi: 10.1158/2159-8290.CD-24-0519 This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research

Recommended Citation

Mazzone, Peter J; Gierada, David; and et al., "Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection." Cancer Discovery. 14, 11. 2224 - 2242. (2024).
https://digitalcommons.wustl.edu/oa_4/4449

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.